Nav: Home

Loss of ARID1A protein drives onset and progress of colon cancer

December 12, 2016

(MEMPHIS, Tenn. - December 12, 2016) A team of scientists has developed a model system in mice that allows them to look closely at how a protein often mutated in human cancer exerts its tumor-silencing effects. Not all cancers are caused by direct changes in the genetic code. Cancers also arise from epigenetic events that influence gene expression in other ways. The new findings, reported online in Nature Genetics, shed light on how epigenetic processes contribute to gene regulation and the onset of colon cancer.

"ARID1A mutations occur in a broad range of human cancers, and it is important to have experimental systems where we can look at how mutation of this gene contributes to disease," said Charles W. M. Roberts, M.D., Ph.D., corresponding author of the study and executive vice president and director of the Comprehensive Cancer Center at St. Jude Children's Research Hospital. "Our results represent an advance in modeling colon cancer and implicate enhancer-mediated gene regulation as a principal tumor suppressor function of ARID1A."

ARID1A is a component of the SWI/SNF chromatin remodeling complex. Chromatin remodeling, which controls how much "read access" the cellular transcription machinery has to DNA sequences, can have profound consequences on gene expression. Genes encoding chromatin remodeling proteins are some of the most frequently mutated genes in human cancer.

The researchers showed that ARID1A functions as a tumor suppressor in the colon of mice but not in the small intestine. They discovered that enhancers, short regions of DNA that specify which genes are turned on in each cell type, were an important part of the interaction of ARID1A with the SWI/SNF chromatin remodeling complex.

Peter J. Park of Harvard Medical School and one of the authors of the study remarked: "Our work showed that when ARID1A is absent, the SWI/SNF chromatin remodeling complex is lost from thousands of enhancers, resulting in reduced expression of nearby genes."

The scientists revealed a broad role for ARID1A in regulating active enhancers whereby loss of ARID1A impairs control of cell identity in the colon and promotes cancer formation.

The new system will be useful in future work. "The system we have developed will be extremely useful to understand why chromatin remodelers are so frequently mutated in cancer, to reveal mechanisms that cause colon cancer growth, and to study potential therapeutic interventions," said Roberts.
The other authors are Radhika Mathur, Burak Han Alver and Agoston Agoston of Harvard Medical School; Adrianna San Roman and Ramesh A. Shivdasani of Harvard Medical School and Dana-Farber Cancer Institute; and Boris Wilson, Xiaofeng Wang of Dana-Farber Cancer Institute.

The research was funded in part by the National Institutes of Health (grants R01CA172152 and R01DK081113), the National Cancer Institute (Cancer Center Support Grant P30CA06516), The Cure AT/RT Now Foundation, the Avalanna Fund, the Garrett B. Smith Foundation, Miles for Mary, the Lind Family, Claudia Adams Barr, Alex's Lemonade Stand and ALSAC.

St. Jude Media Relations contact
Jann Ingmire
Desk: (901) 595-6384
Cell: (901) 356-5716

St. Jude Children's Research Hospital

St. Jude Children's Research Hospital is leading the way the world understands, treats and cures childhood cancer and other life-threatening diseases. It is the only National Cancer Institute-designated Comprehensive Cancer Center devoted solely to children. Treatments developed at St. Jude have helped push the overall childhood cancer survival rate from 20 percent to 80 percent since the hospital opened more than 50 years ago. St. Jude freely shares the breakthroughs it makes, and every child saved at St. Jude means doctors and scientists worldwide can use that knowledge to save thousands more children. Families never receive a bill from St. Jude for treatment, travel, housing and food--because all a family should worry about is helping their child live. To learn more, visit or follow St. Jude at @stjuderesearch.

St. Jude Children's Research Hospital

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Cancer expert says public health and prevention measures are key to defeating cancer
Is investment in research to develop new treatments the best approach to controlling cancer?
UI Cancer Center, Governors State to address cancer disparities in south suburbs
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
Leading cancer research organizations to host international cancer immunotherapy conference
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.

Related Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#SB2 2019 Science Birthday Minisode: Mary Golda Ross
Our second annual Science Birthday is here, and this year we celebrate the wonderful Mary Golda Ross, born 9 August 1908. She died in 2008 at age 99, but left a lasting mark on the science of rocketry and space exploration as an early woman in engineering, and one of the first Native Americans in engineering. Join Rachelle and Bethany for this very special birthday minisode celebrating Mary and her achievements. Thanks to our Patreons who make this show possible! Read more about Mary G. Ross: Interview with Mary Ross on Lash Publications International, by Laurel Sheppard Meet Mary Golda...